CD30 Expression in Germinal Center B-cell-like and non-Germinal Center B-cell-like Subtypes of Diffuse Large B-cell Lymphoma

Patricia Fransisca  Julianty; Maria Francisca Ham; Kusmardi Kusmardi; Agnes Stephanie Harahap

doi:10.3889/oamjms.2020.4645

Authors

Patricia Fransisca Julianty Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Indonesia
Maria Francisca Ham Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Anatomical Pathology, Cipto Mangunkusumo National Central General Hospital, Indonesia
Kusmardi Kusmardi Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Indonesia
Agnes Stephanie Harahap Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Anatomical Pathology, Cipto Mangunkusumo National Central General Hospital, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.4645

Keywords:

CD30, diffuse large B-cell lymphoma, DLBCL, germinal centre B-cell-like, GCB, non-GCB

Abstract

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common and most heterogeneous type of non-Hodgkin lymphoma. With current therapeutic modalities, 30%–40% of DLBCL cases still experience recurrence. The discovery of CD30 expression in DLBCL in several studies has opened up alternative opportunities for new target therapies.

AIM: This cross-sectional study aimed to determine CD30 expression in DLBCL and its difference in expression in germinal center B-cell such as (GCB) and non-GCB subtypes.

METHODS: The sample consisted of 25 GCB and 25 non-GCB cases based on immunohistochemical examination performed at Cipto Mangunkusumo Hospital from 2014 to 2017. CD30 staining was carried out and assessed using tumor cells percentage with positive cutoff values of >0%, >10%, and >20%.

RESULTS: Positive CD30 expression was obtained in 8 (16%), 4 (8%), and 3 (6%), out of 50 DLBCL cases with positive cutoff values of >0%, >10%, and >20%, respectively. We performed Fisher’s exact test to determine CD30 expression in the GCB and non-GCB subtypes and found no significant difference with p > 0.05.

CONCLUSION: Our study found no significant difference between CD30 expression in the GCB and non-GCB subtypes of DLBCL.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Rinaldi I, Hardjolukito ES, Prajogi GB, Giselvania A, Nuhonni SA. Panduan Penatalaksanaan Limfoma non Hodgkin. Jakarta: Komite Nasional Penanggulangan Kanker; 2015. p. 1-8.

Chiu BC, Hou N. Epidemiology and etiology of non- Hodgkin lymphoma. In: Evens AM, Blum KA, editors. Non- Hodgkin Lymphoma Pathology, Imaging, and Current Therapy. Switzerland: Springer; 2015. p. 1-25. https://doi. org/10.1007/978-3-319-13150-4_1

Gascoyne RD, Campo E, Jaffe ES, Staudt LM. Diffuse large B-cell lymphoma, NOS. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA., editors. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th ed. London: IARC; 2017. p. 291-7.

Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller- Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016;101(10):1244-50. https://doi.org/10.3324/ haematol.2016.148809 PMid:27354024

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82. https:// doi.org/10.1182/blood-2003-05-1545 PMid:14504078

Rovira J, Valera A, Colomo L, Setoain X, Rodríguez S, Martínez- Trillos A, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015;94(5):803-12. https://doi.org/10.1007/s00277-014-2271-1 PMid:25501975

Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-24. https://doi.org/10.341 0/f.717989810.793472956 PMid:23343832

Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin- Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-31. https://doi.org/10.1182/ blood-2010-09-297879 PMid:21119107

de Leval L, Gaulard P. CD30+ lymphoproliferative disorders. Haematologica. 2010;95(10):1627-30. https://doi.org/10.3324/ haematol.2010.029256 PMid:20884717

Salas Q, Climent F, Tapia G, Riasol M, Mercadal S, Domingo E. CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like. Hematol Oncol. 2017;35:290-1. https://doi.org/10.1002/hon.2439_19

Gong QX, Wang Z, Liu C, Li X, Lu TX, Liang JH, et al. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J Clin Pathol. 2018;71(9):795- 801. https://doi.org/10.1136/jclinpath-2018-205039 PMid:29666157

Hao X, Wei X, Huang F, Wei Y, Zeng H, Xu L, et al. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS One. 2015;10(5):e0126615. https://doi.org/10.1371/ journal.pone.0126615 PMid:25974110

Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, et al. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Hum Pathol. 2017;60:160-6. https://doi.org/10.1016/j.humpath.2016.10.009 PMid:27816715

van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603. https://doi.org/10.1038/bcj.2017.85 PMid:28885612

Gouveia GR, Siqueira SA, Pereira J. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 2012;34(6):447-51. https://doi. org/10.5581/1516-8484.20120111 PMid:23323070

Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146-71. https://doi. org/10.1016/j.critrevonc.2012.12.009 PMid:23375551

Chen P, Jiang MQ, Ruan XZ, Cai NL, Ye XW, Pan YN, et al. The phenotypes of germinal center B-cell-like (GCB) and non-GCB failed to predict the survival of patients with diffuse large B-cell lymphoma in the rituximab era. Int J Clin Exp Med. 2017;10:13564-70.

Wang XJ, Seegmiller AC, Reddy NM, Li S. CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(1):39-47. https://doi.org/10.1111/ejh.12680 PMid:26340843

Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman- Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: A retrospective study of 167 cases. Leuk Lymphoma. 2013;54(11):2405-11. https://doi.org/10.3109/1042 8194.2013.778407 PMid:23432725

Bartlett NL, Sharman JP, Oki Y, Advani RH, Bello CM, Winter JN, et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim result in patient with DLBCL and other B-Cell lymphoma. Blood. 2013;122:848. https://doi.org/10.1182/ blood.v122.21.848.848